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Background: Cell surface glycans are known to play vital roles in muscle membrane stability and muscle disease,
but to date, roles for glycans in muscle regeneration have been less well understood. Here, we describe a role for
complex gangliosides synthesized by the Galgt1 gene in muscle regeneration.
Methods: Cardiotoxin-injected wild type (WT) and Galgt1−/− muscles, and mdx and Galgt1−/−mdx muscles, were
used to study regeneration in response to acute and chronic injury, respectively. Muscle tissue was analyzed at
various time points for morphometric measurements and for gene expression changes in satellite cell and muscle
differentiation markers by quantitative real-time polymerase chain reaction (qRT-PCR). Primary cell cultures were
used to measure growth rate and myotube formation and to identify Galgt1 expression changes after cardiotoxin
by fluorescence-activated cell sorting (FACS). Primary cell culture and tissue sections were also used to quantify
satellite cell apoptosis.
Results: A query of a microarray data set of cardiotoxin-induced mouse muscle gene expression changes identified
Galgt1 as the most upregulated glycosylation gene immediately after muscle injury. This was validated by qRT-PCR
as a 23-fold upregulation in Galgt1 expression 1 day after cardiotoxin administration and a 16-fold upregulation in
6-week-old mdx muscles. These changes correlated with increased expression of Galgt1 protein and GM1 ganglioside
in mononuclear muscle cells. In the absence of Galgt1, cardiotoxin-induced injury led to significantly reduced myofiber
diameters after 14 and 28 days of regeneration. Myofiber diameters were also significantly reduced in Galgt1-deficient
mdx mice compared to age-matched mdx controls, and this was coupled with a significant increase in the loss of
muscle tissue. Cardiotoxin-injected Galgt1−/− muscles showed reduced gene expression of the satellite cell marker Pax7
and increased expression of myoblast markers MyoD, Myf5, and Myogenin after injury along with a tenfold increase in
apoptosis of Pax7-positive muscle cells. Cultured primary Galgt1−/− muscle cells showed a normal growth rate but
demonstrated premature fusion into myofibers, resulting in an overall impairment of myofiber formation coupled with
a threefold increase in muscle cell apoptosis.
Conclusions: These experiments demonstrate a role for Galgt1 in skeletal muscle regeneration and suggest that
complex gangliosides made by Galgt1 modulate the survival and differentiation of satellite cells.
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Skeletal muscle displays a remarkable potential to regen-
erate after injury, and satellite cells, the predominant
stem cells in adult skeletal muscle, play an essential role
in this process [1-3]. Satellite cells normally reside in
the niche between the skeletal myofiber membrane and
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unless otherwise stated.predominantly of laminin 211 (α2, β1, γ1) and collagen IV
(α1, α2) [4-8]. When a myofiber is injured beyond repair
due to membrane rupture, mechanical insult, or aberrant
calcium homeostasis, the resulting necrosis of skeletal
myofibers is coupled with myofiber clearance by invading
immune cells and the stimulation of asymmetric satellite
cell division to generate myoblasts that will ultimately fuse
to form new skeletal myofibers and new satellite cells that
will replenish the muscle stem cell niche. In response to
acute injury, newly regenerated contractile skeletal myofi-
bers are formed over a period of about 2 weeks [2,9-12].
Certain compounds, including the snake peptide cardio-
toxin (CTX), can mimic the aberrant calcium homeostasisentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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chronize the induction of muscle regeneration [13,14].
In the muscular dystrophies, impaired regeneration,
coupled with chronic muscle damage, can lead to muscle
wasting, which involves the loss of muscle tissue and its
replacement with extracellular matrix or fat [15]. Muscle
wasting in the muscular dystrophies drives the develop-
ment of muscle weakness and ultimately death. Muscle
wasting, which likely occurs due to an imbalance be-
tween muscle degeneration and regeneration, is a hall-
mark of Duchenne muscular dystrophy (DMD). DMD is
caused by mutations or deletions in the dystrophin
(DMD) gene that give rise to an absence of dystrophin
protein expression in skeletal and cardiac muscle [16,17].
The most commonly used DMD animal model is the mdx
mouse [18-20]. The mdx mouse muscle undergoes
chronic cycles of degeneration coupled with muscle regen-
eration. These cycles begin at about 3 weeks of age and
peak at 4–6 weeks of age, when a severe period of muscle
damage occurs. This is followed by a more subdued, but
chronic, disease process throughout the remainder of the
mouse’s lifespan [21]. Introduction of secondary gene dele-
tion or transgene overexpression has implicated a number
of additional genes, including utrophin, telomerase, integ-
rin α7, sarcospan, Galgt2, and Cmah, amongst others, as
modulators of mdx disease severity [22-32].
The important cellular mechanisms involved in muscle
regeneration, satellite cell activation and differentiation,
myoblast migration and fusion, and myofiber growth
are mediated by signaling molecules including Akt and
Wnt kinases, mTOR, Notch receptors, and their down-
stream signals [33-37]. While at least some cell signaling
processes at the membrane involved in muscle regener-
ation are well described, roles for cell surface glycans,
with the exception of syndecan proteoglycans and gly-
cosaminoglycan endosulfatases [38-44], remain poorly
understood. This stands in contrast with the large num-
ber of studies demonstrating roles for glycans in mediating
muscle membrane stability and causing muscle disease
[31,32,45-47]. Complex gangliosides are good candidates
for mediating aspects of muscle regeneration. Gangliosides
have been shown to be able to modulate cell-cell interac-
tions, cell signal transduction, and the activity of mem-
brane ion channels in numerous cell types, including
myoblasts [48-55]. GM2, GD2, and all down-stream com-
plex gangliosides, including GM1, require the enzymatic
activity encoded by the Galgt1 gene for their production
[56,57]. Galgt1 has clear roles in mediating the binding of
complex gangliosides to endogenous sialic acid-binding
lectins that are known to control important aspects of
nervous system development, for example axon guidance,
axon stability, and axonal regeneration [53,57-60]. In this
study, we demonstrate dynamic and pronounced changes




Anti-ganglioside GM1 antibody was purchased from
Millipore (345757). Rabbit polyclonal antibody to Galgt1
peptide CQVRAVDLTKAFDAEE was made in our lab
by immunizing rabbits with KLH-conjugated peptide, after
which antibody was purified over peptide-conjugated resin
as previously described [61]. Anti-mouse Pax7 antibody
was a gift from Dr. Michael Rudnicki (Ottawa Health
Research Institute). Anti-mouse integrin α7 conjugated
to fluorescein isothiocyanate (FITC) was purchased
from MBL International (K0046-4) and R & D Systems
(FAB3518F). Anti-mouse CD11b conjugated to FITC and
Rat anti-Ertr7 were gifts from Dr. Jill Rafael-Fortney (The
Ohio State University). Rat anti-mouse Ly-6A/E conju-
gated to FITC (Sca1, 553335), rat anti-mouse CD45
conjugated to PE-Cy7 (552848), rat anti-mouse CD31 con-
jugated to APC (551262), and rat anti-mouse CD16/CD32
Fc block (553142) were purchased from BD Biosciences.
All secondary antibodies conjugated to fluorophores were
purchased from Jackson ImmunoResearch. Rhodamine-
conjugated α-bungarotoxin was purchased from Life
Technologies. Sections from normal human and Duchenne
muscular dystrophy muscle biopsies from clinical speci-
mens archived as part of the United Dystrophinopathy
Project were obtained in accordance with approval from
the Institutional Review Board.
Mice
All animal experiments were conducted after approval
from the Institutional Animal Use and Care Committee
(IACUC) at The Research Institute at Nationwide
Children’s Hospital. Mice lacking Galgt1 (Galgt1−/−) were
obtained from Consortium for Functional Glycomics
(www.functionalglycomics.org) and were originally made
by Proia and colleagues [57,62]. mdx and wild type
(C57Bl/6) mice were purchased from Jackson Laboratories.
Galgt1−/−mdx mice were obtained by interbreeding of
Galgt1−/− mice with mdx mice. Six-week-old, 3-month-
old, and 6-month-old animals were used for wild type
(WT), Galgt1−/−, mdx, and Galgt1−/−mdx experiments as
indicated.
Cardiotoxin-induced muscle regeneration
Two-month-old animals were used for cardiotoxin injec-
tion experiments. Cardiotoxin, from Naja mossambica
mossambica venom, was purchased from Sigma-Aldrich
(C9759). It was diluted to a 10-μM concentration in
phosphate-buffered saline (PBS) and injected intramus-
cularly into the gastrocnemius, tibialis anterior, or quad-
riceps muscles in a volume of 50 μl (gastroc or quad) or
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4, 7, 14, and 28 days after cardiotoxin injection, snap frozen
in liquid nitrogen-cooled isopentane, and sectioned at
8 μm in cross section on a cryostat for histological analysis.
Mock-injected muscles from control animals were har-
vested at these same time points as controls.
Histology
Muscles were dissected from tendon to tendon, mounted
on OCT, and snap frozen in liquid nitrogen-cooled isopen-
tane. Muscles were cross-sectioned on a cryostat at 8-μm
thickness and mounted on slides for staining. For immuno-
staining, sections were blocked in 3 mg/ml bovine serum
albumin (BSA) in PBS. Primary antibodies were diluted in
3 mg/ml BSA/PBS and sections incubated overnight
at 4°C. After washing in PBS, sections were stained with a
secondary antibody, added at a dilution of 1:250, for 1 h.
After washing, slides were mounted in Prolong Gold
Antifade with 4’,6-diamidino-2-phenylindole (DAPI) and
visualized on a Zeiss Axiophot epifluorescence microscope
using fluorescein-, rhodamine-, or DAPI-specific optics.
For hematoxylin and eosin (H & E) staining, cryostat-cut
8-μm muscle cross sections were first fixed in 10% neutral-
buffered formalin. After washing in tap water, slides were
stained with Gill’s 3 Hematoxylin for 2 min, washed in tap
water, then bluing agent, and again in tap water. Sections
were then stained in eosin for 1 min and excess stain
removed by dipping in 30% ethanol, after which the sec-
tions were dehydrated in 70%, 90%, 95%, and 100%
ethanol. The sections were cleared in xylene and mounted
in the xylene-based mounting media Cytoseal.
Quantification of muscle morphometry
Myofiber diameter and central nuclei measurements
were carried out and quantified using Zeiss AxioVision
Rel.4.8 software as previously described [32]. H & E im-
ages were photographed at × 20 magnification for such
measurements. Briefly, muscle sections from at least
four separate planes of the injected muscle were counted
in total and averaged to create single average data points
for each measure, and the average of these measures
from all animals per time point or condition was then
used to determine the average myofiber diameter, the
percentage of myofibers with central nuclei, the number
of myofibers per unit area, or the percentage of non-
muscle area. For CTX experiments comparing wild type
and Galgt1−/− muscles, and for experiments comparing
mdx and Galgt1−/−mdx muscles, six muscles were aver-
aged per condition, with 1,600–3,600 total myofibers
counted per condition.
Fluorescence Activated Cell Sorting (FACS)
The limb muscles of three WT mice were injected with
10-μM cardiotoxin and compared to WT animals injectedwith an equivalent volume of PBS. One day after injec-
tion, the muscles were removed, minced, and digested
with 5 mg/ml collagenase IV and 1.2 U/ml Dispase for
30 min at 37°C. The reaction was stopped by dilution
with DMEM, filtration of cells through a 70-μm mem-
brane and then a 40-μm cell strainer, and centrifugation
in horse serum to remove enzymes from the cells. Cells
were stained after washing in 0.5% BSA/PBS. Cells were
blocked with Mouse BD Fc Block (BD Pharmingen
553141) at a concentration of 2 μl/106 cells on ice for
10 min followed by staining with fluorophore-conjugated
primary antibody at a concentration of 2 μl/106 cells
for 10 min on ice. Cells were then washed, resus-
pended, and filtered in fluorescence-activated cell sorting
(FACS) tubes. Propidium iodide (PI, 2 μg/ml) was added
just before sorting to identify dead cells. Cells were first
gated based on side scatter and forward scatter then
based on the height and width. PI-positive (dead) cells
were removed prior to further analysis. Cells were sorted
for Sca1+ and Sca1− fractions and each fraction was
further sorted for CD31+, CD45+, and CD31−CD45−.
Fractions were collected and analyzed for Galgt1 mRNA
using quantitative real-time polymerase chain reaction
(qRT-PCR) as previously described [63]. FACS ana-
lysis was repeated with gating for CD31−APC and
CD45−PE Cy7 and the CD31−CD45− fractions, with sort-
ing for integrin α7 against side scatter. The integrin
α7+CD31−CD45−, integrin α7−CD31−CD45−, integrin
α7−CD31+CD45−, and integrin α7−CD31−CD45+ fractions
were collected and analyzed for Galgt1 mRNA using
qRT-PCR as before [63].
Semi-quantitative real-time polymerase chain reaction
(qRT-PCR)
Gastrocnemius muscles were homogenized in TRIzol
(Invitrogen) and total RNA was extracted and purified
using either RNeasy Mini or Micro kits (Qiagen) ac-
cording to the manufacturer’s instructions. The qual-
ity of RNA was determined by electrophoresis using
6000 Nano LabChip kit on Bioanalyzer 2100 (Agilent).
The samples without RNA degradation were used to
synthesize cDNA using High Capacity Reverse Tran-
scriptase kit (Applied Biosystems). Taqman ABI 7500 se-
quence detection system (Applied Biosystems) was used for
real-time qPCR measurements on the samples using the
delta-delta CT method [64]. qRT-PCR probes for Galgt1
and 18S RNA have been described in previous publi-
cations [32,65]. Primers for dystrophin (Mm01216926_m1),
Pax7 (Mm00834079_m1), Myf5 (Mm00435125_m1), MyoD
(Mm00440387_m1), Myogenin (Mm00446194_m1), and
Myh3 (Mm01332463_m1) were purchased from Applied
Biosystems. 18S was used as an internal control. Mea-
sures shown are replicates of three to four muscles per
condition.
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Terminal deoxynucleotidyl transferase (TUNEL) staining
was performed according to the manufacturer’s instruc-
tions using the Click-iT® TUNEL Alexa Fluor® 488
Imaging Assay (Life Technologies, C10245). For Pax7-
TUNEL co-staining, TUNEL staining was done prior to
Pax7 staining, which was done as previously described
[66]. Replicates shown are averages of six muscles per
condition for tissue staining or of three to six replicates
per condition for cell culture experiments.
Muscle cell isolation
Gastrocnemius, quadriceps, tibialis anterior (TA), and
triceps were dissected from WT and Galgt1−/− mice as
previously described [61]. The skeletal muscles were col-
lected in ice-cold sterile PBS and dissected muscles were
minced in a sterile laminar-flow hood using aseptic con-
ditions. The minced muscles were digested in a solution
containing 1.2 U/ml Dispase and 5 mg/ml collagenase
IV. The minced tissue was incubated with enzymes
at 37°C for 30 min with intermittent pipetting every
10 min, followed by addition of DMEM/F12 media + 10%
heat-inactivated horse serum + 1% penicillin-streptomycin
solution. The solution was then filtered through 70-μm
cell strainer and then a 40-μm cell strainer. Cells were
then centrifuged at 1,500 rpm at 4°C for 10 min. The cell
pellet was resuspended in 0.5% BSA/PBS and overlayed on
100% heat-inactivated horse serum and centrifuged at
220 × g at 4°C for 10 min. The pellet was then washed in
0.5% BSA/PBS and centrifuged at 1,500 rpm at 4°C for
10 min and resuspended in growth media (DMEM/F-
12 + 10% FBS + 4% chick embryo extract + 1% P/S).
Cells were pre-plated on uncoated tissue culture plates,
with muscle-cell-enriched supernatant removed after fibro-
blasts were allowed to adhere for 20 min. The pre-plating
step was repeated if needed to obtain pure muscle cell cul-
tures. Purified muscle cells were then plated on 0.1%
collagen-1-coated tissue culture plates. As in our previous
studies [61], such cultures typically showed an excess of
90% positive staining for c-met, a muscle cell marker.
Muscle cell growth rate and fusion assays
To measure the growth rate of isolated muscle cells,
cells extracted and purified from WT and Galgt1−/− skel-
etal muscles were grown in the growth media (DMEM/
F-12 + 10% FBS + 4% chick embryo extract + 1% P/S)
and were counted at three different time points (1, 2,
and 3 days post-plating). For the muscle cell fusion
assay, cells were grown in the growth media till they
reached 100% confluence and were then switched to fu-
sion media (×1 DMEM/F-12 + 2% horse serum + 1%
P/S). Skeletal myofibers were analyzed at four time
points—Day 0 (just before addition of fusion media),
Day 1 (1 day after addition of fusion media), Day 3, andDay 6. Sixteen equivalent fields of view were evaluated
per well with at least three wells evaluated per time point
and per genotype. Data shown are averages of six experi-
ments per condition, normalized to baseline cell number
on Day 0 in each instance.
Statistics
All determinations of significance were done by ANOVA
with post hoc Bonferroni analysis and/or unpaired t-tests.
A P value of less than or equal to 0.05 was considered
significant.
Results
Galgt1 and GM1 expression are increased in regenerating
skeletal muscle
We originally queried the publically available Children’s
National Medical Center Affymetrix microarray data set
developed by Hoffman and colleagues to assess gene ex-
pression changes after CTX-induced muscle regener-
ation in wild type mice (http://microarray.cnmcresearch.
org, now http://pepr.cnmcresearch.org [67,68]). We ana-
lyzed changes in the 1,769 glycosylation-related genes
listed on the glycan microarray from the Consortium for
Functional Glycomics (http://www.functionalglycomics.org),
which includes known glycosyltransferase, glycosidase,
and glycan metabolism genes, as well as mammalian
lectins and some glycoproteins where glycan functions
have been described, using this database. Of the glyco-
sylation genes queried, Galgt1 was the most elevated
relative to control, with a greater than 50-fold increase in
signal in the first day after CTX treatment that remained
elevated for about 14 days (Figure 1A). To validate this
finding, we measured levels of Galgt1 gene expression by
qRT-PCR in WT C57Bl/6 mouse muscles injected with
CTX at 1, 4, 7, 14, and 28 days post-injection and com-
pared expression to untreated muscle (Day 0) (Figure 1B).
Galgt1 expression was elevated 23-fold at 1 day post-CTX
injection, and, much like the microarray data, showed sig-
nificantly elevated levels in the first 14 days after CTX. The
induction of Galgt1 expression declined as regeneration
progressed, nearing baseline again by Day 28, a time at
which muscle regeneration is typically complete.
We next stained skeletal muscles taken at different
days after CTX injection with an antibody to Galgt1
protein or with an antibody to GM1, a complex ganglio-
side that requires Galgt1 activity for its expression [69]
(Figure 1C). GM1 staining was chosen to reflect Galgt1
activity as antibodies to GM2 and GD2 can also cross-
react with glycans made by Galgt2, another glycosyl-
transferase in the Galgt1 gene family, while antibodies
to GM1 do not [69]. As shown previously, antibodies to
Galgt1 protein and GM1 ganglioside both stained the
neuromuscular junction (NMJ) in control muscle (un-
injected Day 0) [63]. This was confirmed by co-staining
Figure 1 Expression of Galgt1 during cardiotoxin-induced muscle regeneration. (A) Galgt1 signal data from the publicly available Children’s
National Medical Center Affymetrix microarray study on regenerating mouse muscle after cardiotoxin-induced injury. (B) qRT-PCR measurement
of the fold change in the expression of Galgt1 gene in WT muscle 1, 4, 7, 14, or 28 days after cardiotoxin-induced muscle injury. (C) Wild type
gastrocnemius muscle was stained with antibody to Galgt1-dependent complex ganglioside GM1, Galgt1 protein, or with secondary antibody
alone (control) after cardiotoxin-induced injury of wild type muscle. Errors in (B) are SEM averaged from six muscles per condition with two to
three measures per muscle. ***P < 0.001, Bar is 50 μm.
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shown). On Day 1 after CTX injection, Galgt1 and GM1
staining were both increased on intramuscular mono-
nuclear cells. This staining of mononuclear cells was also
present on Day 4 and Day 7, though here, myofiber stain-
ing was also evident. By Day 14 and Day 28, both GM1
and Galgt1 staining were primarily localized to regions in-
cluding the NMJ, just as at Day 0 (Figure 1C). Thus,
Galgt1 protein and GM1, a ganglioside product of Galgt1
activity, were both transiently elevated in muscles after
CTX addition, much as would be expected given the
dramatic increase in Galgt1 gene expression.
Galgt1 and GM1 expression are increased in dystrophic
skeletal muscle
We next assessed Galgt1 and GM1 expression in
dystrophin-deficient mouse (mdx) and human (DMD)
skeletal muscles, where chronic cycles of muscle regener-
ation occur (Figure 2). In mdx skeletal muscle, expression
of Galgt1 protein and GM1 ganglioside were increased
in mononuclear cells (Figure 2A), much as we had
previously observed in CTX-induced wild type muscle
(Figure 1C). Staining for Galgt1 and GM1 was absent
in Galgt1−/−mdx muscles, which were used to demon-
strate antibody specificity. Galgt1 gene expression was
upregulated 16-fold in 6-week-old mdx muscle and five-
fold in 3-month-old mdx muscle relative to age-matchedWT muscles (Figure 2B). The increased expression of
GM1 seen in mdx mice also occurred in muscles of DMD
patients when compared to otherwise normal human con-
trols (Figure 2C). In all cases, background staining with
secondary antibody alone (control) showed no significant
staining (Figure 2C). Unfortunately, mRNA extracted from
these human muscle samples was of insufficient quality to
allow qRT-PCR measures of Galgt1 gene expression.
Galgt1-deficient muscles show altered regeneration in
acute and chronic muscle injury models
To test whether increased Galgt1 expression was im-
portant for muscle regeneration, we compared regener-
ation in WT and Galgt1-deficient (Galgt1−/−) mice in
response to acute muscle injury induced by CTX
(Figure 3). In response to CTX, muscles of Galgt1−/− mice
were still able to regenerate, showing that Galgt1 is not es-
sential for skeletal muscle regeneration. There was, how-
ever, a significant difference in the extent of regeneration
between time-matched CTX-treated Galgt1−/− and WT
muscles (Figure 3A). The average myofiber diameter of
Galgt1−/− muscles was significantly smaller than WT on
Day 14 (Figure 3B) and at Day 28 (Figure 3D) after CTX.
A distribution curve of muscle diameters was plotted
to see the range and frequency of muscle sizes in
WT and Galgt1−/− mice. At Day 14 (Figure 3C) and at Day
28 (Figure 3E) post-CTX, the Mini-Feret diameters of
Figure 2 GM1 and Galgt1 expression in dystrophic skeletal muscle. (A) Immunostaining of GM1 ganglioside and Galgt1 protein in 6-week-old
mdx and Galgt1−/−mdx skeletal muscle. (B) qRT-PCR comparison of Galgt1 gene expression in WT and mdx skeletal muscle at 6 weeks and 3 months of
age. (C) GM1 and secondary antibody (control) staining in muscle sections obtained from patients with Duchenne muscular dystrophy (DMD) or from
otherwise normal human muscle. Errors in (B) are SEM averaged from six muscles per condition with two to three measures per muscle. ***P < 0.001,
Bar is 50 μm.
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There was no any evidence of muscle hypertrophy in
Galgt1−/− muscles at any time after CTX. Thus, although
the absence of Galgt1 did not abolish muscle regeneration,
it did alter the rate and/or extent to which muscle regener-
ation occurred.
To assess whether regeneration was altered by the
loss of Galgt1 in a chronic injury model, we interbred
mdx and Galgt1−/− mice to obtain double knockout
(Galgt1−/−mdx) mice (Figure 4). In young Galgt1−/−mdx
mice (6 weeks), a time at which muscle damage in mdx
mice is more severe [21], there was a marked increase
in necrotic areas containing very high-density mono-
nuclear cell infiltrates when compared to mdx littermates
(Figure 4A). This increase was still present, though less
pronounced, in Galgt1−/−mdx animals at 6 months of age
(Figure 4A). Interestingly, the percentage of myofibers
with centrally located nuclei, a measure of the extent of
muscle regeneration, was not significantly changed at
6 weeks of age but was changed at 6 months of age in
Galgt1−/−mdx mice compared to age-matched mdx con-
trols (Figure 4B). The average myofiber diameter, by con-
trast, was significantly changed in Galgt1−/−mdx muscles
at both ages (Figure 4C). Similarly, at both 6 weeks and
6 months, the percentage area within the muscle not con-
taining skeletal myofibers, a measure of muscle damageand wasting, was increased in Galgt1−/−mdx mice com-
pared to mdx (Figure 4D). The fact that mdx mice show
more profound muscle damage in the early interval
at 4–6 weeks of age may explain some of the age-
related differences in these measures, but the results
with Galgt1−/−mdx mice reiterate the finding of reduced
muscle growth found with CTX injury in Galgt1−/− mice
and have additionally the finding of increased muscle tis-
sue loss, a finding not found in CTX-treated Galgt1−/−
muscles. Cumulatively, these data support the notion that
loss of Galgt1 alters the kinetics and/or the extent of
muscle regeneration both in acute and chronic models of
muscle damage.
Galgt1 is overexpressed in muscle cells following
muscle injury
We next used FACS to determine which intramuscular
mononuclear cell types overexpress Galgt1 during muscle
regeneration in response to CTX (Figure 5). To do this,
WT skeletal muscles were injected with CTX and mono-
nuclear cells were sorted by FACS 1 day later and com-
pared to cells isolated and sorted from non-CTX-injected
controls (vehicle only). In each instance, cells were first
gated for Sca1 expression (Sca1+ and Sca1−). Sca1 is a
marker for mesenchymal stem cells. Sca1+ and Sca1−
cell populations were then sorted and collected
Figure 3 Muscle regeneration after cardiotoxin-induced injury in normal and Galgt1-deficient mouse muscle. (A) Hematoxylin and Eosin
staining of wild type (WT) and Galgt1-deficient (Galgt1−/−) mouse muscle at various days after cardiotoxin-induced injury. (B) Average myofiber
diameter of WT and Galgt1−/− gastrocnemius muscle and (C) distribution of myofiber diameters at Day 14 after cardiotoxin-induced injury.
(D) Average myofiber diameter of WT and Galgt1−/− gastrocnemius muscle and (E) distribution of myofiber diameters at Day 28 after
cardiotoxin-induced injury. Errors in (B) and (D) are SEM from six muscles per condition with 1,600–3,200 total myofibers counted per condition.
**P < 0.01, ***P < 0.001, Bar is 200 μm.
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CD31+, Sca1−CD45+, and Sca1−CD31−CD45− (data not
shown). CD31 is a marker for endothelial cells and
CD45 is a marker for immune cells. The mRNA from
various CTX-treated fractions was analyzed for Galgt1
expression using qRT-PCR and compared to the same
fractions isolated from non-CTX-treated controls. Of
these, Galgt1 expression was only significantly increased inthe Sca1−CD31−CD45− CTX-treated fraction (data not
shown). Since the major cell population in this fraction
would be muscle cells (satellite cells and myoblasts) and
intramuscular fibroblasts, cells were next sorted for
CD31+, CD45+, CD31−CD45−integrin α7+, and CD31−
CD45−integrin α7− cells to separate the muscle cell popu-
lation (CD31−CD45−integrin α7+) from the endothelial
(CD31+), immune cell (CD45+), and fibroblast-containing
Figure 4 Muscle phenotypes in young and old mdx and Galgt1-deficient mdx muscles. (A) Hematoxylin and eosin staining of cross
sections of gastrocnemius muscle in young (6 weeks) and old (6 months) mdx and Galgt1−/−mdx animals. (B) Average percentage central nuclei
in mdx and Galgt1−/−mdx gastrocnemius at 6 weeks and 6 months of age. (C) Average Mini-Feret myofiber diameters in mdx and Galgt1−/−mdx
gastrocnemius muscle at 6 weeks and 6 months of age. (D) Average percentage of non-muscle area present in muscle sections in mdx and
Galgt1−/−mdx muscles at 6 weeks and 6 months of age. Errors in (B)–(D) are SEM from six muscles per condition with 1,600–3,200 total myofibers
counted per condition. *P < 0.05, **P < 0.01, ***P < 0.001, NS not significant, Bar is 50 μm.
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CD45−integrin α7+ population was the only cell type that
showed an increase in Galgt1 expression relative to non-
CTX-treated muscle, with over a sixfold average increase
(Figure 5B). None of the other three cell types showed
any increase in Galgt1 expression in cells taken fromCTX muscles when compared to non-CTX-treated con-
trols. To verify this result, we double immunostained for
GM1 with integrin α7 (muscle cell marker), CD11b
(immune cell marker, including macrophages), Ertr7
(fibroblast marker), or Sca1 (mesenchymal cell marker)
(Figure 5A). GM1 staining was localized in cells also
Figure 5 Galgt1 gene expression is elevated in muscle cells during muscle regeneration. (A) Immunostaining with antibodies to GM1 (red)
and antibodies to cell-specific markers (green) for muscle cells (integrin α7), immune cells (CD11b), fibroblasts (Ertr7), or mesenchymal stem cells
(Sca1), with DAPI (blue) nuclear stain, 1 day after cardiotoxin injection into the gastrocnemius muscle. Three-color merged images are shown on
the right. (B) qRT-PCR comparison of Galgt1 gene expression in FACS-sorted cell populations after 1 day of cardiotoxin-induced injury compared
to the same populations sorted from untreated controls. ***P < 0.001 (comparing CD31−CD45−integrin α7+ to any of the other shown conditions).
Errors in (B) are SEM averaged from four experiments per condition with two to three measures per muscle. Bar is 50 μm.
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expressing Sca1, Ertr7, or CD11b. Similar results were ob-
tained for Galgt1 protein-double immunostaining (data
not shown). GM1 staining sometimes appeared in a punc-
tate pattern, which may be consistent with non-uniform
membrane expression, such as one might observe in lipid
rafts. These data demonstrate that muscle cells have in-
creased levels of Galgt1 and GM1 and largely contribute to
the marked elevation of Galgt1 expression in regenerating
muscle.
Regenerating Galgt1−/− muscle has altered expression of
satellite and myoblast cell markers
As we had identified muscle cells as the major cell type
showing increased Galgt1 expression during CTX-inducedregeneration (Figure 5), we next compared gene expression
for a marker of satellite cells (Pax7), several markers of
myoblasts (MyoD, Myf5, and Myogenin), a marker of
early differentiating myofibers (embryonic myosin, Myh3),
and a marker of mature myofibers (dystrophin) at various
times after CTX-induced injury (Figure 6). Pax7 expres-
sion was reduced in Galgt1-deficient muscles at 4, 7,
and 14 days post-CTX injury relative to WT (P < 0.001
at Day 4 and 14). By contrast, expression of MyoD and
Myf5 was elevated at Days 1, 4, and 7 after CTX, as
was Myogenin at Days 4 and 7 (P < 0.001 for all).
Expression of embryonic myosin (Myh3) was also elevated
in Galgt1−/− muscles at Days 4 and 7 (P < 0.001 for both),
while expression of dystrophin was not changed at
these times. These data suggest that while Galgt1
Figure 6 Altered gene expression of satellite cell, myoblast, and early myofiber markers in regenerating Galgt1−/− muscle. Wild type
(WT) and Galgt1-deficient (Galgt1−/−) muscles were injected with cardiotoxin and gene expression measured at Day 1, 4, 7, 14, and 28, relative to
control untreated muscle (Day 0). Gene expression was compared for Pax7, a satellite cell marker; MyoD, Myf5, and Myogenin (Myog), myoblast
cell markers; Myh3 (embryonic myosin), a marker for early differentiating myofibers; and Dystrophin (Dmd), a marker for mature myofibers. Data
represent averages of three to four experiments per condition, with two to three measures per point.
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after CTX-induced injury, this differentially affects
the expression of markers for satellite cells and
myoblasts. Such data would be consistent with an over-induction of myoblast differentiation at the expense of
self-renewing satellite cells in regenerating Galgt1−/−
muscle. Several additional experiments also pointed to
this conclusion.
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extent in the absence of Galgt1
We next performed studies on isolated muscle cells
purified from WT and Galgt1-deficient (Galgt1−/−) mus-
cles (Figure 7). Isolated cells were pre-plated to remove
intramuscular fibroblasts and to enrich for muscle cells.
Cells were grown to confluency and then switched to
low-serum-containing media to induce myoblast fusion
into myofibers, as previously described [61]. WT muscle
cells formed long, thick, and abundant myofibers after
6 days in fusion media, whereas Galgt1−/− muscle cells
formed less abundant and often shorter and smaller
myofibers (Figure 7A–C). Interestingly, on Day 1, after
placement of confluent cultures in fusion media, the
number of myofibers (Figure 7C) and the area of fused
myofibers per visual field (Figure 7B) were significantly
higher in cells isolated from Galgt1−/− muscle when
compared to WT. On Day 3 and Day 6, however,
Galgt1−/− cultures showed significantly reduced num-
bers of myofibers with smaller overall area (Figure 7B, C).
To ensure that this difference in fusion between WT and
Galgt1−/− myoblasts was not due to difference in myo-
blast growth, we measured the growth rate of WT and
Galgt1−/− cells cultured in growth media and found no
significant difference (Figure 7D). Assessment of myo-
blast migration in a classical scratch assay also showed
no significant change (data not shown). These data are
consistent with the premature differentiation of cul-
tured muscle cells into myofibers in Galgt1−/− muscles.Figure 7 Altered differentiation of cultured Galgt1−/− muscle cells. (A)
Galgt1-deficient (Galgt1−/−) primary muscle cells 6 days after placement in
the visual field at 1, 3, or 6 days after addition of differentiation media. (C)
or 6 days after addition of differentiation media. (D) Growth rate of isolated
n = 6 experiments in (B)–(D), with three to six replicates per data point. *PIncreased apoptosis in satellite cells in Galgt1−/− muscle
in vitro and in vivo
One possible cause of reduced myofiber formation over
time would be an increase in satellite cell or myoblast
cell death during the induction of differentiation. To in-
vestigate whether Galgt1-deficient muscle cells were
more susceptible to apoptosis during the induction of
differentiation, we performed TUNEL staining on cul-
tured muscle cells in vitro as well as in CTX-treated
skeletal muscle in vivo (Figure 8). Isolated muscle cells
from Galgt1−/− muscles showed a threefold increase in
TUNEL staining relative to cells isolated from WT mus-
cles after addition of differentiation media (Figure 8A, C).
Such TUNEL-positive Galgt1−/− cells showed classical
signs of apoptosis, including increased chromatin con-
densation and nuclear fragmentation (Figure 8A). The
permeabilization conditions used here led to significant
cytoplasmic TUNEL staining in some cells. When tissue
sections from CTX-injected muscles were stained for
TUNEL, there was a 7.6–10.5-fold increase in the num-
ber of stained cells in Galgt1−/− muscles compared to
WT at Days 4, 7, and 14 post-injury (Figure 8B, E). To as-
sess if Pax7+ satellite cells had increased apoptosis, we
co-stained cells in WT and Galgt1−/− muscles for TUNEL
and Pax7 (Figure 8D). At Days 4 and 7 in WT muscle, a
significant percentage of TUNEL-positive apoptotic cells,
about 40%, were Pax7-positive. The overall number of
such TUNEL-positive cells, however, was quite small
(Figure 8E). By contrast, in Galgt1−/− muscle, the vastPhase-contrast images of cultured confluent wild type (WT) and
myofiber differentiation media. (B) Area of myofibers per unit area of
Number of myofibers present per unit area of the field of view at 1, 3,
primary muscle cells cultured in growth media. Errors are SEM for
< 0.01, ***P < 0.001, Bar is 50 μm.
Figure 8 Increased apoptosis of Galgt1-deficient muscle cells in vitro and in vivo. (A) TUNEL and Hoechst co-staining on primary muscle cell
cultures isolated from wild type (WT) and Galgt1-deficient (Galgt1−/−) skeletal muscle 1 day after placement in differentiation media. (B) Double
immunostaining for Pax7 and TUNEL of Galgt1−/− skeletal muscle after CTX injection. Apoptotic nuclei are visualized with green fluorescent TUNEL
staining, with Pax7+ staining in red. Arrows indicate regions with co-staining. (C) Quantification of TUNEL+ nuclei per visual field in WT and Galgt1−/−
myoblast cultures 1 day after addition of differentiation media. (D) Percentage of cells positive for both Pax7 and TUNEL, relative to all TUNEL+ cells, at
various days after cardiotoxin injection of wild type (WT) and Galgt1-deficient (Galgt1−/−) muscle. (E) Fold difference in TUNEL+ nuclei in the Galgt1−/−
skeletal muscle, relative to WT, at various days after CTX injection. Errors in (C) are SEM for n= 6 experiments with three to four replicates per condition and
SEM for n= 6 experiments in (D) and (E) with three to four sections analyzed per muscle. *P< 0.05, **P< 0.01, ***P< 0.001. Bar is 50 or 12.5 μm (insert).
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cells were also Pax7-positive, and the number of
TUNEL-positive cells was significantly increased relative
to WT at Days 4, 7, and 14. It is important to point out
that there were still many Pax7+ cells that were not
stained for TUNEL in Galgt1−/− CTX-treated muscles and
that regeneration likely progressed due to the presence
of these remaining, non-dying, satellite cells. These data
demonstrate that the majority of muscle cells under-
going apoptosis during regeneration in Galgt1−/− muscles
are Pax7-positive satellite cells and suggest that Galgt1
modulates satellite cell survival during muscle regeneration.
Discussion
Here we have described a new role for complex ganglio-
sides made by Galgt1, a gene encoding a β1,4GalNAcglycolipid glycosyltransferase, in muscle regeneration.
Galgt1 expression was dramatically elevated in the first
few days after induction of acute muscle regeneration by
cardiotoxin and was elevated in mdx muscles, which
undergo chronic regeneration as well. During regener-
ation, elevated Galgt1 expression was identified in muscle
cells, but not in intramuscular fibroblasts, immune cells,
or mesenchymal stem cells. Moreover, studies of muscle
cells isolated from normal and Galgt1-deficient muscles
demonstrated that Galgt1 is required for proper muscle
cell differentiation and survival; regenerating Galgt1−/−
muscles showed a deficit in gene expression for the
satellite cell marker Pax7 and increased gene expression
for myoblast markers MyoD, Myf5, and Myogenin,
cultured muscle cells from Galgt1−/− mice showed prema-
ture fusion into myofibers which resulted in less robust
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from Galgt1−/− mice showed an order of magnitude
increase in the apoptosis of Pax7-positive cells during the
regeneration process. The end result, both for acute and
chronic muscle regeneration models, was a deficit in re-
generation with increased populations of smaller caliber
myofibers. In Galgt1−/−dystrophin-deficient (mdx) muscles,
this was also coupled with increased loss of muscle tissue.
Further work will be needed to more carefully analyze the
possible mechanisms of action, but this study clearly shows
that Galgt1 plays a role in the regenerative process in
skeletal muscle and identifies complex gangliosides made
by Galgt1 as potential targets for therapeutic interventions
to stimulate aspects of muscle regeneration.
Our findings are consistent with previous studies im-
plicating other types of glycans, including glycosamino-
glycans and N-linked glycans, in satellite cell function
during muscle regeneration. The results reported here
showing reduced Pax7 expression and increased MyoD
expression in Galgt1−/− muscle, for example, are similar
to the studies of Denis and colleagues on Mgat5-deficient
mice, which had reduced satellite cell number with a
bias towards increased MyoD expression at the ex-
pense of Pax7 [70]. Mgat5 affects the formation of
β1,6-GlcNAc-branched N-linked glycans and would
not directly affect the biosynthesis of gangliosides made
by Galgt1; nevertheless, it is possible that these pathways
might intersect through a less-direct mechanism. Emerson
and colleagues have shown that inhibition of heparin
sulfate 6-O-endosulfatases (Sulfs) in Sulf1/Sulf2 double
knockout mice increases the number of Pax7-positive
satellite cells as well as increasing fibroblast growth factor
(FGF) signaling [43]. Ai and colleagues have further shown
a complex differential regulation of canonical and non-
canonical Wnt signaling pathways in Sulf1/2 double mu-
tant mice, with a bias towards premature differentiation of
satellite cells and formation of myofibers with smaller
overall area after cardiotoxin-induced injury [44], akin to
what we observed in these studies in Galgt1-deficient
mice. Work by Olwin, Brandan, Velleman, and others
suggests that mice or cells lacking the proteoglycans
Syndecan-3 or Syndecan-4 show impairment of satellite
cell division and/or differentiation, including altered
induction of MyoD expression and localization as well as
impaired myofiber formation [38,39,42,71,72]. These
syndecans could impact signaling of multiple regeneration
signaling pathways, including NotchR, FGF, and Wnt [42].
Gangliosides, through their ability to orient proteins in
lipid rafts on the cell membrane, might interact with any
or all of these other glycan-dependent pathways to
regulate their ability to govern various signaling functions
in muscle cells. Future work will be required to delin-
eate the possible pathways by which complex ganglio-
sides, N-linked glycans, and glycosaminoglycans mightintersect to modulate these vital regenerative signaling
pathways.
A number of studies support such roles for complex
gangliosides in muscle cell function. Gangliosides are reg-
ulated differentially through the various stages of muscle
cell differentiation [73-75]. Since GD1a and GM1 expres-
sion are both increased in cultured myoblasts just before
fusion [75], and as they both require Galgt1 for their bio-
synthesis [56], their elevated expression likely arises from
increased Galgt1 gene expression. GM1 has also been
shown to be present on the lamellipodia of myoblasts, and
affecting the clustering and dispersal of lipid rafts has been
shown to be important for myoblast fusion [76-78]. Stud-
ies on the fusion-resistant fu-1 rat myoblast cell line have
demonstrated that there is a consistent decrease in the
levels of glycosphingolipids in these cells and that they
have lost the ability to differentiate and express the
markers of differentiation [75,79,80]. Glycosylation inhibi-
tors like tunicamycin also impair myoblast cell fusion [81],
and no myoblast fusion is observed in certain lectin-
resistant muscle cell mutants [79,80,82]. Many other
studies suggest that gangliosides can alter intracellular
signaling by kinases [49,50,52,53,83,84], including kinases
known to affect muscle regeneration such as Akt [85,86]
and mTOR [87]. Modulation of these and other signaling
pathways would also impact muscle cell growth or differ-
entiation. One current obstacle to muscle cell therapies is
the inefficient muscle engraftment of transplanted stem or
induced pluripotent stem cells (iPS) [88]. This too would
be an avenue worth exploring as regards Galgt1 function
as a potential stimulator of muscle regeneration, as it
appears unlikely that the logarithmic increase in Galgt1
gene expression seen in muscle cells a day after injury
in vivo would be maintained once these cells were isolated
and amplified for prolonged periods in culture.
Conclusions
This work demonstrates a role for Galgt1 during muscle
regeneration. Galgt1 gene expression is dramatically
elevated in both acute and chronic mouse models of
muscle injury, as is GM1, a ganglioside that requires
Galgt1 activity for its biosynthesis. Loss of Galgt1 in
mice leads to impaired muscle regeneration in both
acute and chronic muscle injury models, and loss of
Galgt1 is coupled to premature differentiation and in-
creased apoptosis of satellite cells in vitro and in vivo.
These data support the notion that complex ganglio-
sides generated by Galgt1 play modulatory roles during
muscle regeneration and might be therapeutic targets in
myopathies where muscle regeneration is impaired or
insufficient.
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